Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Equillium stock | $4.59

Own Equillium stock in just a few minutes.

Fact checked

Equillium, Inc is a biotechnology business based in the US. Equillium shares (EQ) are listed on the NASDAQ and all prices are listed in US Dollars. Equillium employs 26 staff and has a market cap (total outstanding shares value) of USD$115.2 million.

How to buy shares in Equillium

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Equillium. Find the stock by name or ticker symbol: EQ. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Equillium reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.59, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Equillium, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Equillium. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Equillium share price

Use our graph to track the performance of EQ stocks over time.

Equillium shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$4.59
52-week rangeUSD$2.2 - USD$19.22
50-day moving average USD$4.7342
200-day moving average USD$6.2797
Wall St. target priceUSD$16.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.413

Buy Equillium shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Equillium stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Equillium price performance over time

Historical closes compared with the close of $4.59 from 2020-12-09

1 week (2021-01-15) -11.73%
1 month (2020-12-23) -2.34%
3 months (2020-10-23) -21.40%
6 months (2020-07-22) -65.70%
1 year (2020-01-22) 10.87%
2 years (2019-01-22) -60.19%
3 years (2018-01-19) N/A
5 years (2016-01-19) N/A

Equillium financials

Gross profit TTM USD$0
Return on assets TTM -22.68%
Return on equity TTM -44.79%
Profit margin 0%
Book value $3.16
Market capitalisation USD$115.2 million

TTM: trailing 12 months

Shorting Equillium shares

There are currently 480,722 Equillium shares held short by investors – that's known as Equillium's "short interest". This figure is 29.8% down from 684,913 last month.

There are a few different ways that this level of interest in shorting Equillium shares can be evaluated.

Equillium's "short interest ratio" (SIR)

Equillium's "short interest ratio" (SIR) is the quantity of Equillium shares currently shorted divided by the average quantity of Equillium shares traded daily (recently around 763050.79365079). Equillium's SIR currently stands at 0.63. In other words for every 100,000 Equillium shares traded daily on the market, roughly 630 shares are currently held short.

However Equillium's short interest can also be evaluated against the total number of Equillium shares, or, against the total number of tradable Equillium shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Equillium's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Equillium shares in existence, roughly 20 shares are currently held short) or 0.0335% of the tradable shares (for every 100,000 tradable Equillium shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Equillium.

Find out more about how you can short Equillium stock.

Equillium share dividends

We're not expecting Equillium to pay a dividend over the next 12 months.

Equillium share price volatility

Over the last 12 months, Equillium's shares have ranged in value from as little as $2.2 up to $19.22. A popular way to gauge a stock's volatility is its "beta".

EQ.US volatility(beta: 1.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Equillium's is 1.731. This would suggest that Equillium's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Equillium overview

Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site